NCT04605575: Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 208 | RoW | Pyrotinib 320mg + Vinorelbine, Pyrotinib 400mg + Vinorelbine, Pyrotinib plus Vinorelbine | Sun Yat-sen University | Breast Cancer, Pyrotinib, Breast Diseases, Vinorelbine, HER2-positive Breast Cancer | 08/23 | 12/23 | | |